Niewydolność nerek w przebiegu szpiczaka mnogiego = Renal failure in multiple myeloma

Agnieszka Surowiec, Łukasz Wołowiec, Bartosz Kochański, Anna Kałużna, Krystian Kałużny, Alicja Krakowska, Walery Zukow

Abstract


Surowiec Agnieszka, Wołowiec Łukasz, Kochański Bartosz, Kałużna Anna, Kałużny Krystian, Krakowska Alicja, Zukow Walery. Niewydolność nerek w przebiegu szpiczaka mnogiego = Renal failure in multiple myeloma. Journal of Education, Health and Sport. 2016;6(1):262-270. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.45356

http://ojs.ukw.edu.pl/index.php/johs/article/view/3346

https://pbn.nauka.gov.pl/works/710506

 

 

 

The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 755 (23.12.2015).

755 Journal of Education, Health and Sport eISSN 2391-8306 7

© The Author (s) 2016;

This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium,

provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License

(http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial

use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 01.01.2016. Revised 12.01.2016. Accepted: 31.01.2016.

 

 

 

Niewydolność nerek w przebiegu szpiczaka mnogiego

Renal failure in multiple myeloma

 

Agnieszka Surowiec1,Łukasz Wołowiec2, Bartosz Kochański3, Anna Kałużna3, Krystian Kałużny3, Alicja Krakowska3,Walery Zukow4

 

1Studenckie Koło Naukowe Diagnostyki i Terapii Niewydolności Serca, II Katedra Kardiologii, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w Toruniu

2II Katedra Kardiologii, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w Toruniu

3Katedra i Klinika Rehabilitacji, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w Toruniu

4Instytut Kultury Fizycznej, Wydział Kultury Fizycznej, Zdrowia i Turystyki, Uniwersytet Kazimierza Wielkiego w Bydgoszczy

 

Streszczenie

Pierwszą manifestacją kliniczną szpiczaka mnogiego (MM) może być niewydolność nerek (z ang. renal failure RF). Podwyższone stężenie kreatyniny w surowicy jest już często obecne w momencie rozpoznania choroby aż u 20-50% pacjentów z MM. MM charakteryzuje się proliferacją monoklonalnych komórek plazmatycznych, wytwarzających białko M i rozwija się etapami. W pierwszym etapie komórki B stają się nieśmiertelne z powodu translokacji chromosomalnej w locus ciężkiego łańcucha immunoglobulinowego. Rokowanie u pacjentów z kreatyniny w surowicy> 2,0 mg/dl. Ponadto, pacjenci z niewydolnością nerek są często eliminowani z agresywnych czy też wysokodawkowych protokołów chemioterapeutycznych ze względu na ich toksyczność.

 

Abstract

One of the first symptoms of multiple myeloma (MM) can be renal insufficiency (RI). Elevated concentration of serum creatinine states is already present at the time of diagnosis in 20–50% of patients with MM. MM is characterised by monoclonal proliferation of plasma cells which are producing monoclonal immunoglobulin (M protein). The disease develops in many stages. In the first stage the cells B becomes immortal due to chromosomes translocation in the immunoglobuline heavy chain locus. The prognosis for patients with a serum creatinine >2.0 mg/dL is very bad. Moreover, patients with renal failure are often excluded from aggressive or high-dose chemotherapy protocols because of an expected higher toxicity rate.

 

Słowa kluczowe: szpiczak mnogi, gammapatia monoklonalna, niewydolność nerek.

 

Keywords: multiple myeloma, monoclonal gammopathy, renal failure.


Keywords


szpiczak mnogi, gammapatia monoklonalna, niewydolność nerek, multiple myeloma, monoclonal gammopathy, renal failure.

Full Text:

PDF (Polski)

References


Mollee P. Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev 2009, 30, 93.

Rajkumar S.V., Kyle R.A., Buadi F.K. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010, 85, 945.

Landgren O. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. Hematology Am. Soc. Hematol Educ Program 2010, 2010, 295-302.

Rajkumar S.V. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009, 15, 5606,

Dimopoulos M.A., Terpos E., Chanan-Khan A. I wsp. Renal impairment in patients with multiple myeloma; a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.

Herrera G.A., Senders P.W. Paraproteinemic renal diseases that involve the tabulo-interstitium. Contrib Nephrol 2007, 153, 105-115.

Bradwell A.R., Carr-Smith H.D., Mead G.P. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001, 47, 673-680.

Herrera G.A., Senders P.W. Paraproteinemic renal diseases that involve the tabulo-interstitium. Contrib Nephrol 2007, 153, 105-115.

Dimopoulos M.A., Kyle R.A., Anagnostopoulos A., Treon S.P. Diagnosis and management of Waldenstrom’s macroglobulinemia. J Clin Oncol 2005, 23, 1564–1577.

Ghobrial I.M. Are you sure this is Waldenstrom macroglobulinemia? Am J Hematol 2012, 1, 586–594.

Morel P., Duhamel A., Gobbi P. i wsp. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009, 113, 4163–4170.

Audard V., Georges B., Venhille P. i wsp. Rena lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. Clin J Am Soc Nephrol 2008, 3, 1339-1349.

Kastritis E., Anagnostopoulos A., Rousso M. i wsp.. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007, 92, 546–549.

Weber D.M., Dimopoulos M.A., Moulopoulos L.A. i wsp. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997, 96, 810–814.

Rajkumar S.V., Larson D., Kyle R.A. Diagnosis of smoldering multiple myeloma. N Engl J Med 2001, 365, 474–475.

Chatterjee M., Honemann D., Lentzsch S. i wsp. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gpl30/STAT3 pathway. Blood 2002, 100, 3311-3318.

Børset M., Seidel C., Hjorth-Hansen H. i wsp. The role of hepatocyte growth factor and its receptor c-met in multiple myeloma and other blood malignancies. Leuk Lymphoma 1999, 32, 249-256.

Cozzolino F., Torcia M., Aldinucci D. i wsp. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989, 74, 380-387.

Singhal S., Mehta J. Multiple myeloma. Clin J Am Soc Nephrol 2006, 1, 1322-1330.

Terpos E., Dimopoulos M.A. Myeloma bone disease: patho-physiology and management. Ann Oncol 2005, 16, 1223-1231.

Hu L., Shi Y., Hsu J. i wsp. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003, 101, 3126-3135.

Dimopoulos M.A., Terpos E. Renal insufficiency and failure. Hematology Am Soc Hematol Educ Program 2010, 2010, 431–436.

Knudsen L.M., Hippe E., Hjorth M. i wsp. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994, 53, 207–212.

Dimopoulos M.A., Kastritis E., Rosinol L. i wsp. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008, 22, 1485–1493.

Batuman V. The pathogenesis of acute kidney impairment in patients with multiple myeloma. Adv Chronic Kidney Dis 2012, 19, 282–286.

Dimopoulos M.A., Delimpasi S., Katodritou E. i wsp. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014, 25, 195–200.

Eleutherakis-Papaiakovou V., Bamias A., Gika D. i wsp. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007, 48, 337–341.

Roussou M., Kastritis E., Christoulas D. i wsp. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010, 34, 1395–1397.

Niesvizky R., Vij V, Martin T. i wsp. Carfilzomib pharmacokinetics, safety and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: final results (abstract no. 0890). Haematologica 2011, 96, 370–371.

Feest T.G., Burge P.S., Cohen S.L. Successful treatment of myeloma kidney by diuresis and plasmaphoresis. British Medical Journal 1976, 1, 503–504.

Dimopoulos M.A., Terpos E., Chanan-Khan A. i wsp. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010, 28, 4976–4984.

Harris E., Behrens J., Samson D. i wsp. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. British Journal of Haematology 2003, 122, 160–161.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 Journal of Education, Health and Sport

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616

POL-index 2011 - 2014

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655

BASE 2011 - 2014

https://www.base-search.net/Search/Results?lookfor=Journal+of+Health+Sciences+%28Radom%29&type=all&oaboost=1&ling=1&name=&thes=&refid=dcrespl&newsearch=1

http://elibrary.ru/contents.asp?titleid=37467

http://journal.rsw.edu.pl/index.php/JHS/issue/archive

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844

Find a library that holds this journal: http://worldcat.org/issn/23918306

Journal Language(s): English 

PBN Poland

https://pbn.nauka.gov.pl/sedno-webapp/journals/49068

POL-index

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4

BASE

https://www.base-search.net/Search/Results?join=AND&bool0[]=AND&lookfor0[]=2391-8306&type0[]=all&page=11&l=pl&oaboost=1&refid=dcpagepl

Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2  www.ukw.edu.pl Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy http://ojs.ukw.edu.pl/index.php/johs  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.

http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase Index.com.

Website: www.infobaseindex.com

Universal Impact Factor 1.78 for year 2012. (http://www.uifactor.org/AppliedJournals.aspx)

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski

(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)